BenevolentAI
BenevolentAI utilizes AI technologies for medicine discovery. The firm has over 20 various drug studies in the pipeline. HQ - London.
NewsHeat chart
- Week
- Month
- Year
- Media news
- Corp news
- Combo news
The data in the chart above is based on data derived from our proprietary XP calculation model and may be changed, adjusted and updated without prior notice
Company Valuation
- Valuation
- Share Price
- Cumulative Funding
The data in the tables and charts is based on data from public sources and although we make every effort to compile the data, it may not coincide with the actual data of the issuer.
Investors
Goldman Sachs
Woodford Investment Management
Lundbeck
Upsher Smith Laboratories
Lansdowne Partners
Temasek HoldingsNews related to BenevolentAI
BenevolentAI • 25 Apr 2022BenevolentAI Begins Trading On Euronext Amsterdam - Benzinga
BenevolentAI is a leading, clinical-stage AI-enabled drug discovery company headquartered in London, with a research facility in Cambridge (UK) and an office in ...
https://www.benzinga.com/pressreleases/22/04/n26779294/benevolentai-begins-trading-on-euronext-amsterdamBenevolentAI • 14 Jan 2022BenevolentAI announces 3-year collaboration expansion with ...
The expansion builds on the collaboration initiated in 2019 and adds systemic lupus erythematosus (SLE) and heart failure (HF) to ongoing work to identify ...
https://www.streetinsider.com/Press+Releases/BenevolentAI+announces+3-year+collaboration+expansion+with+AstraZeneca+focused+on+systemic+lupus+erythematosus+and+heart+failure/19455518.htmlBenevolentAI • 23 Dec 2021Pharmaceutical AI Platform and Software Global Market Insights ...
BenevolentAI. Atomwise. AI Therapeutics. Insilico Medicine. Recursion Pharmaceuticals. Lantern Pharma. Adaptive Biotechnologies....
https://uk.finance.yahoo.com/news/pharmaceutical-ai-platform-software-global-132100228.html